Single arm phase 2 trial of atezolizumab and bevacizumab in Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lu¬¬ng cancer in patients with disease progression after osimertinib"

Administered By

Awarded By

Contributors

Start/End

  • May 15, 2020 - January 31, 2025